Publikation

Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study.

Wissenschaftlicher Artikel/Review - 06.02.2024

Bereiche
PubMed
DOI
Kontakt

Zitation
Günther R, Wurster C, Brakemeier S, Osmanovic A, Schreiber-Katz O, Petri S, Uzelac Z, Hiebeler M, Thiele S, Walter M, Weiler M, Kessler T, Freigang M, Lapp H, Cordts I, Lingor P, Deschauer M, Hahn A, Martakis K, Steinbach R, Ilse B, Roediger A, Bellut J, Nentwich J, Zeller D, Muhandes M, Baum T, Koch J, Schrank B, Fischer S, Hermann A, Kamm C, Naegel S, Mensch A, Weber M, Neuwirth C, Lehmann H, Wunderlich G, Stadler C, Tomforde M, George A, Gross M, Pechmann A, Kirschner J, Türk M, Schimmel M, Bernert G, Martin P, Rauscher C, Meyer Zu Hörste G, Baum P, Löscher W, Flotats-Bastardas M, Köhler C, Probst-Schendzielorz K, Goldbach S, Schara-Schmidt U, Mueller-Felber W, Lochmüller H, von Velsen O, SMArtCARE study group, Kleinschnitz C, Ludolph A, Hagenacker T. Long-term efficacy and safety of nusinersen in adults with 5q spinal muscular atrophy: a prospective European multinational observational study. Lancet Reg Health Eur 2024; 39:100862.
Art
Wissenschaftlicher Artikel/Review (Englisch)
Zeitschrift
Lancet Reg Health Eur 2024; 39
Veröffentlichungsdatum
06.02.2024
eISSN (Online)
2666-7762
Seiten
100862
Kurzbeschreibung/Zielsetzung

Evidence for the efficacy of nusinersen in adults with 5q-associated spinal muscular atrophy (SMA) has been demonstrated up to a period of 16 months in relatively large cohorts but whereas patients reach a plateau over time is still to be demonstrated. We investigated the efficacy and safety of nusinersen in adults with SMA over 38 months, the longest time period to date in a large cohort of patients from multiple clinical sites.